Financial Results for the First Quarter
of Fiscal Year Ending March 31, 2025 (FY2024)

from the beginning

Financial Results for the FirstQuarter of Fiscal Year Ending March 31, 2025 (FY2024)

• Forward-Looking Statements and Use of Document

• Highlights

• P&L

• OP Variance Analysis (Q1): Sustained demand contributing to increased sales

• Change to Exchange Rate Used for Elimination of Unrealized Gains on Inventory

• Revenue by Region: Steady progress in all regions, with transient demand also contributing

• C&V:Both sales and profits exceeded planned figures, driven by Europe and the U.S.

• TMCS:Revenues and profits increased due to the effects of pricing measures, including sales increases due to one-time factors

• TBCT:Sales expanded due to strong performance by the blood center business

• Awareness of the Current Environment

Reference

• P&L (QoQ)

• SG&A (QoQ)

• SG&A (YoY)

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and Amortization, R&D Expenses

• Cash Flows (Q1)

• Foreign Exchange Sensitivity

rogo